The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

Stivarga

Despite Frances high threat level hotel stays reached 1071 million
Biotech

Phase 3 hepatocellular carcinoma fail crushes Onxeo

The setback wiped about 50% off Onxeo’s share price as investors adjusted to the diminished expectations for the doxorubicin-loaded nanoparticles.
Nick Paul Taylor Sep 12, 2017 10:12am
colorectal

ASCO: Chi-Med touts fruquintinib's phase 3 safety edge

Jun 5, 2017 6:24pm